source
- InnoCare’s TYK2 inhibitor soficitinib meets primary endpoint in phase 2 vitiligo trialInnoCare Pharma announced that its TYK2 inhibitor soficitinib achieved the primary endpoint in a phase 2 study of non‑segmental vitiligo conducted at sites in China. The trial evaluated daily oral…
- Mirador Therapeutics announces partnership to acquire Kira drug, positioning it against TavneosMirador Therapeutics, a San Diego‑based biotech focused on immune diseases and backed by more than $650 million in venture capital, has disclosed a new element of its development pipeline. The com…